Literature DB >> 33575814

Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Tatsuo Kawai1, Katherine J Elliott1, Rosario Scalia1, Satoru Eguchi2.   

Abstract

A disintegrin and metalloproteases (ADAMs) are key mediators of cell signaling by ectodomain shedding of various growth factors, cytokines, receptors and adhesion molecules at the cellular membrane. ADAMs regulate cell proliferation, cell growth, inflammation, and other regular cellular processes. ADAM17, the most extensively studied ADAM family member, is also known as tumor necrosis factor (TNF)-α converting enzyme (TACE). ADAMs-mediated shedding of cytokines such as TNF-α orchestrates immune system or inflammatory cascades and ADAMs-mediated shedding of growth factors causes cell growth or proliferation by transactivation of the growth factor receptors including epidermal growth factor receptor. Therefore, increased ADAMs-mediated shedding can induce inflammation, tissue remodeling and dysfunction associated with various cardiovascular diseases such as hypertension and atherosclerosis, and ADAMs can be a potential therapeutic target in these diseases. In this review, we focus on the role of ADAMs in cardiovascular pathophysiology and cardiovascular diseases. The main aim of this review is to stimulate new interest in this area by highlighting remarkable evidence.

Entities:  

Keywords:  Angiotensin; Atherosclerosis; Endothelium; Heart disease; Hypertension; Inflammation; Signal transduction; Vascular biology

Mesh:

Substances:

Year:  2021        PMID: 33575814      PMCID: PMC9301870          DOI: 10.1007/s00018-021-03779-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  341 in total

1.  ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3.

Authors:  F Loechel; J W Fox; G Murphy; R Albrechtsen; U M Wewer
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

2.  MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE.

Authors:  Jeffrey Odenbach; Xiang Wang; Stephan Cooper; Fung Lan Chow; Tatsujiro Oka; Gary Lopaschuk; Zamaneh Kassiri; Carlos Fernandez-Patron
Journal:  Hypertension       Date:  2010-11-15       Impact factor: 10.190

Review 3.  ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors.

Authors:  Haruhiko Ohtsu; Peter J Dempsey; Satoru Eguchi
Journal:  Am J Physiol Cell Physiol       Date:  2006-07       Impact factor: 4.249

4.  ADAM19 expression in human nephrogenesis and renal disease: associations with clinical and structural deterioration.

Authors:  W B W H Melenhorst; M C van den Heuvel; A Timmer; S Huitema; M Bulthuis; W Timens; H van Goor
Journal:  Kidney Int       Date:  2006-08-09       Impact factor: 10.612

5.  Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction.

Authors:  Yudai Shimoda; Mamoru Satoh; Motoyuki Nakamura; Tomonari Akatsu; Katsuhiko Hiramori
Journal:  Clin Sci (Lond)       Date:  2005-04       Impact factor: 6.124

6.  Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection.

Authors:  Jörg W Bartsch; Dirk Wildeboer; Garrit Koller; Silvia Naus; Andrea Rittger; Marcia L Moss; Yuji Minai; Harald Jockusch
Journal:  J Neurosci       Date:  2010-09-08       Impact factor: 6.167

7.  Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling.

Authors:  Leslie F Jackson; Ting Hu Qiu; Susan W Sunnarborg; Aileen Chang; Chunlian Zhang; Cam Patterson; David C Lee
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

8.  ADAM33 gene polymorphisms and mortality. A prospective cohort study.

Authors:  Sylwia M Figarska; Judith M Vonk; Cleo C van Diemen; Dirkje S Postma; H Marike Boezen
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

9.  Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases.

Authors:  Rory R Koenen; Jessica Pruessmeyer; Oliver Soehnlein; Line Fraemohs; Alma Zernecke; Nicole Schwarz; Karina Reiss; Alisina Sarabi; Lennart Lindbom; Tilman M Hackeng; Christian Weber; Andreas Ludwig
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

10.  Phosphatidylserine exposure is required for ADAM17 sheddase function.

Authors:  Anselm Sommer; Felix Kordowski; Joscha Büch; Thorsten Maretzky; Astrid Evers; Jörg Andrä; Stefan Düsterhöft; Matthias Michalek; Inken Lorenzen; Prasath Somasundaram; Andreas Tholey; Frank D Sönnichsen; Karl Kunzelmann; Lena Heinbockel; Christian Nehls; Thomas Gutsmann; Joachim Grötzinger; Sucharit Bhakdi; Karina Reiss
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

View more
  13 in total

Review 1.  The Role of ADAM17 in Inflammation-Related Atherosclerosis.

Authors:  Bai-Yi Tang; Jin Ge; Yang Wu; Juan Wen; Xiao-Hong Tang
Journal:  J Cardiovasc Transl Res       Date:  2022-06-01       Impact factor: 4.132

Review 2.  Disintegrin and Metalloproteinases (ADAMs [A Disintegrin and Metalloproteinase] and ADAMTSs [ADAMs With a Thrombospondin Motif]) in Aortic Aneurysm.

Authors:  Tolga Kilic; Keisuke Okuno; Satoru Eguchi; Zamaneh Kassiri
Journal:  Hypertension       Date:  2022-05-11       Impact factor: 9.897

3.  Treatment of Sorsby fundus dystrophy with anti-tumor necrosis factor-alpha medication.

Authors:  Richard F Spaide
Journal:  Eye (Lond)       Date:  2021-08-10       Impact factor: 4.456

4.  Expression of ADAM12 in Gastric Cancer and its Relation to Tumor Cell Behavior and Prognosis.

Authors:  Min-Woo Chung; Young-Lan Park; Sun-Young Park; Young-Eun Joo
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

Review 5.  Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.

Authors:  Carmine Savoia; Massimo Volpe; Reinhold Kreutz
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

6.  The Downregulation of ADAM17 Exerts Protective Effects against Cardiac Fibrosis by Regulating Endoplasmic Reticulum Stress and Mitophagy.

Authors:  Chang Guan; Hai-Feng Zhang; Ya-Jing Wang; Zhi-Teng Chen; Bing-Qing Deng; Qiong Qiu; Si-Xu Chen; Mao-Xiong Wu; Yang-Xin Chen; Jing-Feng Wang
Journal:  Oxid Med Cell Longev       Date:  2021-05-06       Impact factor: 6.543

Review 7.  ADAM17, A Key Player of Cardiac Inflammation and Fibrosis in Heart Failure Development During Chronic Catecholamine Stress.

Authors:  Joseph Adu-Amankwaah; Gabriel Komla Adzika; Adebayo Oluwafemi Adekunle; Marie Louise Ndzie Noah; Richard Mprah; Aisha Bushi; Nazma Akhter; Fei Huang; Yaxin Xu; Seyram Yao Adzraku; Iqra Nadeem; Hong Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-13

8.  ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV.

Authors:  Maria Daskou; William Mu; Madhav Sharma; Hariclea Vasilopoulos; Rachel Heymans; Eleni Ritou; Valerie Rezek; Philip Hamid; Athanasios Kossyvakis; Shubhendu Sen Roy; Victor Grijalva; Arnab Chattopadhyay; Scott G Kitchen; Alan M Fogelman; Srinivasa T Reddy; Theodoros Kelesidis
Journal:  PLoS Pathog       Date:  2022-01-07       Impact factor: 6.823

Review 9.  Vascular Stress Signaling in Hypertension.

Authors:  Stephanie M Cicalese; Josiane Fernandes da Silva; Fernanda Priviero; R Clinton Webb; Satoru Eguchi; Rita C Tostes
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

10.  Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.

Authors:  Cristina Almengló; Marinela Couselo-Seijas; Rosa M Agra; Alfonso Varela-Román; José M García-Acuña; Mercedes González-Peteiro; José R González-Juanatey; Sonia Eiras; Ezequiel Álvarez
Journal:  J Mol Med (Berl)       Date:  2021-09-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.